Ranitidine Hydrochloride Recall Expanded to Other Companies

Ranitidine Hydrochloride Recall Expanded to Other Companies

After Sandoz Inc. voluntarily recalled all quantities and lots within expiry of ranitidine hydrochloride due to confirmed contamination of N-Nitrosodimethylamine (NDMA), a probable human carcinogen, three other major companies are recalling ranitidine hydrochloride as well for the same issue.

Sanofi has issued a recall for all Zantac OTC (ranitidine hydrochloride) in the U.S., Perrigo is recalling all ranitidine hydrochloride worldwide, and Dr. Reddy’s is recalling ranitidine hydrochloride nationwide

Ranitidine hydrochloride capsules are indicated for the treatment of duodenal ulcer, benign ulcer, reflux esophagitis, post-operative peptic ulcer, Zollinger-Ellison Syndrome, and other conditions where reduction of gastric secretion and acid output is desirable. 

Relevant to workers’ comp, patients taking opioid pain medications may experience gastrointestinal side effects, requiring a gastrointestinal agent and potentially being prescribed ranitidine hydrochloride.

For further information, visit the FDA online for recall alerts.